Show simple item record

dc.contributor.authorJankowski, Janusz
dc.date.accessioned2020-08-11T15:15:52Z
dc.date.available2020-08-11T15:15:52Z
dc.date.issued2019-08
dc.identifier.citationRatcliffe, E. G. and Jankowski, J. A. (2019) ‘Gastroesophageal reflux disease and Barrett esophagus: an overview of evidence-based guidelines’, Polish archives of internal medicine, 129(7–8), pp. 516–525. doi: 10.20452/pamw.14828.en
dc.identifier.otherPMID 31080232
dc.identifier.urihttps://orda.derbyhospitals.nhs.uk/handle/123456789/2298
dc.descriptionOpen Access article distributed under the terms of the Creative Commons Attribution‑NonCommercial‑ShareAlike 4.0 International License (CC BY‑NC‑SA 4.0) Erratum in: Pol Arch Intern Med. 2020 Jan 31;130(1):98-99. (PMID: 32011607)en
dc.description.abstractGastroesophageal reflux disease is an extremely common condition worldwide, with the published prevalence rates varying from 2.5% in China to 51.2% in Greece. Its economic and morbidity burden is vast, and optimizing care for this condition carries huge financial and patient‑related benefits. The disease can be complicated by progression to Barrett esophagus (BE), a precancerous condition that affects approximately 2% of the population and remains undiagnosed in many individuals. The National Institute of Clinical Excellence has produced guidelines on cost‑effective management of gastroesophageal reflux disease in patients in the United Kingdom, and the Benign Barrett's and Cancer Taskforce consensus was the largest international review of evidence known on the management of benign BE complications. This paper is a review of these guidelines with updates on new evidence. Areas for future development involve risk‑stratifying patients to surveillance, chemoprevention agents, and genetic biomarkers to help decide who will be at highest risk of malignant progression. Evidence supports the safety of proton pump inhibitors for symptom control in the medium term (ie, 9 years) and reducing the risk of progression of BE, while surgical options are cost‑effective treatments for certain patients. Barrett esophagus surveillance should be directed towards high‑risk groups, while those at lower risk may benefit from chemoprevention strategies.en
dc.language.isoenen
dc.subjectBarrett Esophagusen
dc.subjectGastroesophageal Refluxen
dc.subjectPrecancerous Conditionsen
dc.titleGastroesophageal reflux disease and Barrett esophagus: an overview of evidence-based guidelines.en
dc.typeArticleen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record